An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast-ovarian cancer syndrome
South Asian J Cancer
.
2020 Jan-Mar;9(1):6.
doi: 10.4103/sajc.sajc_157_19.
Authors
Vikas T Talreja
1
,
Vanita Noronha
1
,
Amit Joshi
1
,
Vijay Patil
1
,
Kumar Prabhash
1
Affiliation
1
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
PMID:
31956609
PMCID:
PMC6956583
DOI:
10.4103/sajc.sajc_157_19
No abstract available